ARTICLE |
Correspondence to: Julie A. Schneider, 1645 W. Jackson Blvd., Suite 675, Chicago, IL 60612. E-mail: jschneid@rush.edu
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The role of substantia nigra pathology in Alzheimer's disease (AD) is uncertain. Detection of pathology may be obscured by intraneuronal neuromelanin and influenced by stains. We determined methods for optimal visualization of nigral pathology in 45 cases of AD. For detection of Lewy bodies (LBs), we compared ubiquitin and -synuclein immunostains to hematoxylin and eosin (H&E). For neurofibrillary tangles (NFTs) and neuropil threads (NTs), we compared Gallyas silver and paired helical filament (PHF) immunostains, after bleaching of melanin, to modified Bielschowsky, Gallyas, and PHF alone. The number of LB cases was not different using the three stains. However, more LBs per section were detected using
-synuclein (z=4.88, p<0.001). Twice the number of cases exhibited NFT (z=8.21; p<0.001) and the mean NFT number per section was 2.85.2-fold greater, using Gallyas and PHF after bleaching compared to without bleaching (
2=142.17; p<0.001). More NTs (z=6.54; p<0.001) were observed with PHF and Gallyas after bleaching. With optimal methods, we found LBs in 27%, NFTs in 89%, and NTs in all 45 AD cases. We show that detection of nigra pathology is influenced by histological method. Clinicopathological studies using these methods are needed to determine the role of nigral pathology in AD.
(J Histochem Cytochem 50:99106, 2002)
Key Words: substantia nigra, neurofibrillary tangles, neuropil threads, Lewy body, Alzheimer's disease, neuromelanin
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cytoskeletal changes are commonly observed in the substantia nigra (SN) of persons who die of Alzheimer's disease (AD) (-synuclein immunostain to hematoxylin and eosin (H&E). For detection and counts of neurofibrillary tangles (NFTs) and neuropil threads (NTs), we compared Gallyas silver stain and paired helical filament (PHF) immunostain, after the application of bleach, to modified Bielschowsky silver and to Gallyas silver stain and PHF without the use of bleach.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cases and Neuropathological Evaluation
Forty-five cases of AD were obtained from the neuropathology laboratory at the Rush Alzheimer's Disease Center. Subjects had all presented with dementia and had a clinical diagnosis of dementia that was confirmed as probable or definite AD by neuropathological evaluation (see below). Records from these cases did not contain uniform assessment for disease severity, extrapyramidal signs, or a diagnosis of dementia with LBs (
The brains were removed from the calvaria 224 hr (mean postmortem interval 7.8; SD = 5.5) after death and processed using standard protocols. The brainstem was removed at the level of the diencephalicmesencephalic junction and the hemispheres cut into 1-cm coronal slabs. The brainstem and slabs were then fixed in 4% paraformaldehyde for up to 7 days. Multiple cortical regions of brain (including midfrontal, superior temporal, inferior parietal cortices, and hippocampus) were embedded in paraffin, cut into 6-µm sections, mounted on slides, and stained with H&E and modified Bielschowsky silver stain or thioflavin S stain (
Evaluation of the Substantia Nigra
Consecutive 6-µm sections of midbrain, including the substantia nigra, were cut from the available paraffin-embedded block at approximately the level of exit of the third nerve. We applied eight methods of staining to adjacent sections of substantia nigra, including H&E stain, modified Bielschowsky silver stain (-synuclein (Chemicon International, Temecula, CA; 1:3750); and Gallyas silver stain and PHF-1 immunostain after applying bleach to tissue sections to remove neuromelanin (
Gallyas silver staining was performed as originally described (
PHF, ubiquitin, and -synuclein immunostains were performed using the avidinbiotinperoxidase method (ABC Elite; Vector, Burlingame, CA). Briefly, paraffin-embedded tissues were mounted on electrostatically charged slides, deparaffinized, washed, and blocked with normal serum. Sections were then incubated with the primary antibody overnight, washed, incubated with the biotinylated secondary antibody for 1 hr, and then with the avidinbiotinperoxidase complex for 30 min. The chromogen for color development was 3,3'diaminobenzidine. Immunohistochemical controls consisted of sections incubated without primary antibody. Positive controls included neocortical tissue from known cases of AD (for PHF immunostaining) and LB disease (ubiquitin and
-synuclein immunostaining).
Bleaching of the tissue sections for removal of neuromelanin was performed before immunohistochemistry with PHF and Gallyas silver staining (see above). The bleaching procedure was accomplished by 30-min incubation of mounted tissue sections in 0.25% potassium manganese peroxide followed by a 5-min incubation in 5% oxalic acid, as previously described (-synuclein immunostaining. However, these antibodies stained the neuromelanin granules in addition to the inclusions (LBs), rendering no appreciable detection advantage in the use of bleach (personal observations).
Rating of Pathology in the Substantia Nigra
The same examiner (JAS) scored all 45 cases. Cases were separated into two batteries of stains and the examiner was blinded to the results of the initial battery when examining the second battery. The initial battery of stains included H&E for LBs, Bielschowsky silver staining, Gallyas silver staining, and PHF immunostaining for NFTs, and Gallyas silver staining and PHF immunostaining for NTs. Bielschowsky silver staining was not used to assess NTs because the dense staining of axonal elements and vessels interfered with the evaluation of NTs. The second battery of stains included ubiquitin and -synuclein immunostaining for LBs and Gallyas silver staining and PHF immunostaining after applying bleach for removal of neuromelanin for NFTs and NTs.
The total numbers of NFTs and LBs in the 6-µm hemisection were counted using a microscopic field at a magnification of x100. We counted all positive structures within each frame from medial to lateral. We found that we were able to obtain reliable counts without the aid of a grid. The slide was manually moved across the stage in a stepwise manner, to avoid redundancy in counting, until all positive structures were counted. A magnification of x200 was used when clarification was needed for structural identification (see below). The section was first visually scanned at low power to delineate the region of the substantia nigra and note was made if the section was incomplete or was significantly distant from the region of the third nerve exit. Quantitation of NFTs and LBs was completed on each slide from a medial to lateral direction. NFTs were identified when there was positive intraneuronal staining (brownish black on Bielschowsky, Gallyas, and PHF immunostaining; black with bleaching before Gallyas and PHF immunostaining) and a fibrillar morphology. Identification of LBs required a neuronal intracytoplasmic rounded structure (pinkish-red on H&E or brown on immunostaining), typically with a peripheral halo. Because LBs immunostained with ubiquitin and -synuclein do not always show halos (
Neuropil threads (NTs) were scored in the region of substantia nigra exhibiting the greatest density within the hemisection. The slide was first scanned at low power to determine the location of greatest density of NTs within the substantia nigra and then scored on a semiquantitative scale, from 0 (none) to 5 (severe) at a total magnification of x200. A score of 1 = rare NTs or <5 NTs/high-power field (hpf); a score of 2 = slight or about 615 NTs/hpf; a score of 3 = mild or approximately 1635 NTs/hpf; a score of 4 = moderate or about 3550 NTs/hpf; and a score of 5 = severe or about >50 NTs/hpf. NTs were defined as curvilinear structures of narrow width and of variable length that stained brown or black, depending on the staining method.
Statistical Analysis
Our data were quantitative (counts) for LBs and NFTs and semiquantitative (ratings) for NTs. We analyzed these variables as both dichotomous (present/absent) and counts and ratings. The primary outcomes of interest were the ability of different methods to detect (a) more cases with each pathological index, and (b) a greater number of each pathological index. Because this essentially amounts to measuring the same pathological index multiple times from the same subject under different experimental conditions, we employed repeated measures analyses, using the method of generalized estimating equations (
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Lewy Bodies
We found that the number of cases detected with LB pathology did not significantly differ using -synuclein immunostaining compared with H&E or ubiquitin (z=1.37; p=0.085) (Table 1). In addition, ubiquitin immunostaining did not improve case detection rate compared to H&E (z=1.44; p=0.074). Conversely, the type of staining method significantly affected the number of LBs counted in hemisection. We counted a significantly greater number of LBs using
-synuclein compared to H&E and ubiquitin (z=4.88; p<0.001) (Table 1). In addition, ubiquitin immunostaining allowed detection of significantly greater numbers of LBs compared to H&E (z=2.88; p= 0.002). Of those with at least one LB, the median number of LBs was 5.5 using H&E, 10.5 using ubiquitin, and 19.4 using
-synuclein immunostaining.
|
Neurofibrillary Tangles and Neuropil Threads
The number of cases identified with one or more NFTs was highest using Gallyas silver staining and PHF immunohistochemistry in bleached sections (41 and 40 cases, respectively; z=4.06; p<0.001) compared to all of the other methods (Table 2). In addition, NFTs in the substantia nigra were observed in more cases using Gallyas silver staining (n=32) and PHF-1 immunostaining (n=37) compared to modified Bielschowsky silver staining (n=18).
|
The overall numbers of NFTs counted in hemisection was significantly greater using Gallyas and PHF after the bleaching of tissue sections compared to all of the other methods without bleach (z=8.21; p< 0.001; Table 2). The absolute number of NFTs per hemisection observed with Gallyas or PHF after bleaching of melanin was more than 10-fold greater than the number observed by modified Bielschowsky and was more than 2.5 times greater than Gallyas or PHF staining alone (Fig 1A and Fig 1B). Gallyas and PHF after bleaching allowed similar increases in detection of NFTs (33.9 ± 38.8 NFTs vs 30.6 ± 35.8 NFTs; 2=1.86; p=0.173). Gallyas silver staining and PHF immunostaining alone (without prebleaching) allowed detection of a greater number of NFTs on average, per case, compared to Bielschowsky silver staining (z=3.16; p<0.001).
|
The morphology of the NFTs using silver staining and PHF, with or without bleach, most often revealed the typical globose fibrillary structures (Fig 2A and Fig 2B). Using Gallyas after the bleaching of tissue sections additionally revealed small thread-like and linear intraneuronal tangles (Fig 2C). PHF immunostaining, particularly after bleach, also showed small intraneuronal tangle-like inclusions, as well as diffuse or dot-like staining occasionally extending into neuronal processes (Fig 2D).
|
We identified neuropil threads (Fig 3) in the majority of cases of AD. Depending on the method, 88100% of the cases of AD showed at least a few NTs. Semiquantitative estimates of the number of NTs were increased by the use of bleach (z=6.54; p<0.001) as compared to no bleach. In addition, PHF after bleaching allowed visualization of more threads (mean score 3.2 ± 1.4) compared to Gallyas after bleaching (2.3 ± 1.4) (2 = 50.75; p<0.001).
|
The distribution of neurofibrillary pathology within the substantia nigra was not specifically addressed in this study. However, neurofibrillary pathology was observed throughout the hemisection of nigra rather than confined to a particular anatomic locus within the nucleus.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Specific stains and the bleaching of tissue sections to remove neuromelanin before staining dramatically improve detection of LBs and neurofibrillary pathology in the substantia nigra in AD. -Synuclein and ubiquitin immunostaining did not increase the number of cases uncovered with LB pathology. However,
-synuclein and, to a lesser extent, ubiquitin allowed visualization of increased numbers of nigral LBs per case. Pretreatment with bleach significantly increased both the numbers of cases detected with neurofibrillary pathology and the amount of neurofibrillary pathology detected on average per case. Using the bleaching method, approximately 90% of AD cases showed NFTs, with NFT counts approximately 10-fold greater on average per case (compared to unbleached sections), and all cases displayed at least a few NTs.
Few previous studies have investigated detection of nigral pathology in AD comparing different histological stains or tissue bleaching before staining (-synuclein-immunopositive structures was found to exceed that of ubiquitin (
The protein -synuclein is one of the integral components of LBs in Parkinson's disease, LB disease, and AD with LB (
-synuclein-immunopositive, ubiquitin-immunonegative LBs (
-synuclein immunostaining has a higher sensitivity for LBs than ubiquitin. This may be explained partly by the fact that
-synuclein is present at an earlier stage of LB formation, e.g., pale bodies (intracytoplasmic pale eosinophilic inclusions lacking the peripheral halo) often considered a precursor to LBs. Unlike ubiquitin, which may immunostain other neuronal inclusions, e.g., neurofibrillary pathology,
-synuclein immunostaining is relatively specific for LBs (
-Synuclein positivity is, however, also found in oligodendroglial inclusions of multiple system atrophy (
Most previous literature of NFTs in AD suggest that neurofibrillary pathology in the substantia nigra is uncommon (
Improved visualization of nigral neurofibrillary pathology after bleaching could result from unveiling of perikaryal structures or from decreased neuropil staining. The occasional diffuse staining of cell bodies and extensions with PHF immunostaining after bleaching may suggest detection of an earlier stage of NFT development. During neurofibrillary degeneration, differential stages are recognized by ultrastructural and immunohistochemical changes (
The impact of these findings on the pathologic diagnoses of diseases with LBs (e.g., dementia with Lewy bodies) remains uncertain. Although we did not increase case detection for LBs using -synuclein, our study did not include evaluation of the cortex or assess severity of disease, and therefore it remains to be determined whether
-synuclein better detects cases with cortical LBs or nigral LB pathology in asymptomatic or early-stage disease. It is interesting to note that, compared to "pure" AD, there are fewer NFTs in the substantia nigra in cases of AD with nigral LB. Nevertheless, improved detection of neurofibrillary pathology is noted for both groups (Table 3). Fewer neocortical NFTs have been previously reported in AD with LBs (
|
The implications of these findings for clinical pathologic and other research studies, where it is useful to use the most sensitive method to detect pathology, are apparent. Our results support the second Dementia with Lewy Body International Workshop (-synuclein for LB detection in clinicopathological correlative studies. Although the clinical correlate of the number of nigral LB has not been well studied in AD, absolute LB counts in the neocortex using ubiquitin immunohistochemistry may be related to cognitive status in LB disease (
In persons with AD and parkinsonism, the neuropathological substrate underlying the motor disorder often remains speculative (
![]() |
Acknowledgments |
---|
Supported by grants from the National Institute on Aging (AG10161, AG14449, AG09966, AG09466, AG00849) and the Elsie Heller Fund.
We wish to thank Woojeong Bang for assistance with computer programming and Jia-liang Li for assistance in the laboratory.
Received for publication February 20, 2001; accepted August 2, 2001.
![]() |
Literature Cited |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bennett D, Beckett L, Wilson RS, Murray AM, Evans DA (1998) Parkinsonian signs and mortality from Alzheimer's disease. Lancet 351:1631[Medline]
Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239-259[Medline]
Bondareff W, Harrington C, Wischik CM, Hauser DL, Roth M (1994) Immunohistochemical staging of neurofibrillary degeneration in Alzheimer's disease. J Neuropathol Exp Neurol 53:158-164[Medline]
Chang Chui H, Lee Teng E, Henderson V, Moy A (1985) Clinical subtypes of dementia of the Alzheimer type. Neurology 35:1544-1550[Abstract]
Diggle PJ, Liang K-Y, Zeger SL (1994) Analysis of Longitudinal Data. Oxford, Clarendon Press
Forno L, Alvord E (1971) The pathology of Parkinsonism: Some new observations and correlations. In McDowell F, Markhana C, eds. Recent Advances in Parkinson's Disease. Philadelphia, FA Davis, 120-130
Gallyas F (1971) Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung 19:1-8[Medline]
German DC, White CL, III, Sparkman DR (1987) Alzheimer's disease: Neurofibrillary tangles in nuclei that project to the cerebral cortex. Neuroscience 21:305-312[Medline]
Gibb W, Mountjoy C, Mann D, Lees A (1989) The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome. J Neurol Neurosurg Psychiatry 52:193-200[Abstract]
Greenberg SG, Davies P, Schein JD, Binder LI (1992) Hydrofluoric acid-treated PHF proteins display the same biochemical properties as normal
*. J Biol Chem 267:564-569
Hansen LA, Masliah E, Galasko D, Terry RD (1993) Plaque-only Alzheimer's disease is usually the Lewy body variant, and visa versa. J Neuropathol Exp Neurol 52:648-654[Medline]
Hulette C, Mirra S, Wilkinson W, Heyman A, Fillenbaum G, Clark C (1995) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IX. A prospective cliniconeuropathologic study of Parkinson's features in Alzheimer's disease. Neurology 45:1991-1995[Abstract]
Irizarry MC, Growdon W, GomezIsla T, Newell K, George JM, Clayton DF, Hyman BT (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain -synuclein immunoreactivity. J Neuropathol Exp Neurol 57:334-337[Medline]
Ishii T (1966) Distribution of Alzheimer's neurofibrillary changes in the brain stem and hypothalamus of senile dementia. Acta Neuropathol (Berl) 6:181-187[Medline]
Kazee A, Cox C, Richfield E (1995) Substantia nigra lesions in Alzheimer's disease and normal aging. Alzheimer Dis Assoc Disord 9:61-67[Medline]
Kobayashi K, Miyazu K, Fukutani Y, Nakamura I, Yamaguchi N (1992) Gallyas-Schiff stain for senile plaques. Biotech Histochem 67:256-260[Medline]
Leverenz J, Sumi S (1986) Parkinson's disease in patients with Alzheimer's disease. Arch Neurol 43:662-664[Abstract]
Liang K-Y, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13-22
Liu Y, Stern Y, Chun M, Jacobs D, Yau P, Goldman J (1997) Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol 41:368-374[Medline]
Lowe J, Lennox G, Leigh P (1997) Disorders of movement and system degenerations. In Graham D, Lantos P, eds. Greenfield's Neuropathology. Vol 2. 6th ed London, New York, Arnold & Oxford University Press, 281-366
Mayeux R, Stern Y, Spanton S (1985) Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 35:453-461[Abstract]
McKeith IG, Galasko MD, Kosaka K, Perry DS, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, deVos RAI, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 47:1113-1124[Abstract]
McKeith IG, Perry IK, Perry RH (1999) Report of the Second Dementia with Lewy Body International Workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 53:902-905
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479-486[Abstract]
Molsa PK, Marttila RJ, Rinne UK (1984) Extrapyramidal signs in Alzheimer's disease. Neurology 34:1114-1116[Abstract]
Morris J, Drazner M, Fulling K, Grant E, Goldring J (1989) Clinical and pathological aspects of parkinsonism in Alzheimer's disease: A role for extranigral factors? Arch Neurol 46:651-657[Abstract]
Mufson EJ, Mash DC, Hersh LB (1988) Neurofibrillary tangles in cholinergic pedunculopontine neurons in Alzheimer's disease. Ann Neurol 24:623-629[Medline]
Parvizi J, Van Hoesen GW, Damasio A (2001) The selectivity vulnerability of brainstem nuclei to Alzheimer's disease. Ann Neurol 49:53-66[Medline]
Perry RH (1986) Alzheimer's disease and related disorders. Br Med Bull 42:34-41[Medline]
Richards M, Stern Y, Marder K, Cote L, Mayeux R (1993) Relationships between extrapyramidal signs and cognitive function in a community-dwelling cohort of patients with Parkinson's disease and normal elderly individuals. Ann Neurol 33:267-274[Medline]
Samuel W, Galasko D, Masliah E, Hansen L (1996) Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 55:44-52[Medline]
(1997) SAS/STAT® Software: Changes and Enhancements through Release 6.12. Cary, NC, SAS Institute, Inc
Smith MA, RudnickaNawrot M, Richey PL, Praprotnik D, Mulvihill P, Miller CA, Sayre LM, Perry G (1995) Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem 64:2660-2666[Medline]
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) -synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469-6473
Stern Y, Albert M, Brandt J, Jacobs DM, Tang MX, Marder K, Bell K, Sano M, Devanand DP, Bylsma F (1994) Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictor's Study. Neurology 44:2300-2307[Abstract]
Tabaton M, Schenone A, Romagnoli P, Mancardi GL (1985) A quantitative and ultrastructural study of substantia nigra and nucleus centralis superior in Alzheimer's disease. Acta Neuropathol (Berl) 68:218-223[Medline]
Tomlinson BE, Corsellis JAN (1984) Ageing and the dementias. In Hume Adams J, Corsellis JAN, Duchen LW, eds. Greenfield's Neuropathology. London, Edward Arnold, 951-1025
Uchihara T, Kondo H, Ikeda K, Kosaka K (1995) Alzheimer-type pathology in melanin-bleached sections of substantia nigra. J Neurol 242:485-489[Medline]
Wakabayashi K, Yoshimoto M, Tsufi S, Takahashi H (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Let 249:180-182[Medline]
Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schneider JA, Evans DA (2000a) Progression of parkinsonian signs in Alzheimer's disease. Neurology 54:1284-1289
Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schneider JA, Evans DA (2000b) Progression of parkinsonism and loss of cognitive function in Alzheimer's disease. Arch Neurol 57:855-860
Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121-130[Medline]